Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes

Area of Science:

• Biomedical Engineering
• Drug Delivery Systems
• Hepatocyte Biology

Background:

• The hepatocyte asialoglycoprotein receptor mediates receptor-mediated endocytosis of asialoglycoproteins.
• Targeting hepatocytes specifically is crucial for various therapeutic applications.

Purpose of the Study:

• To explore a hepatocyte-specific targeting strategy using asialofetuin (AF) conjugated to pegylated liposomes.
• To evaluate the efficacy of AF-liposomes in targeting hepatocytes via the asialoglycoprotein receptor.

Main Methods:

• Asialofetuin (AF) was conjugated to polyethylene glycol-functionalized phospholipids.
• AF-liposomes were characterized for size, monodispersity, and loaded with imaging agents.
• In vitro and in vivo studies were conducted using HepG2 cells and rats, respectively.

Main Results:

• AF-liposomes demonstrated specific binding and cellular uptake by HepG2 cells, dependent on temperature and inhibited by free AF.
• Hepatocyte-specific targeting and internalization of AF-liposomes were confirmed in vivo in rats.
• Non-pegylated liposomes accumulated in reticuloendothelial system cells, unlike AF-liposomes.

Conclusions:

• AF-conjugated, pegylated liposomes represent a promising strategy for hepatocyte-specific targeting.
• This approach effectively avoids the reticuloendothelial system, enhancing delivery to hepatocytes.
• The asialoglycoprotein receptor mediates the targeted uptake of AF-liposomes both in vitro and in vivo.